Daiichi Sankyo UK has launched Sevikar HCT, the first three-in-one combination therapy available in the UK for the management of hypertension. The new treatment combines olmesartan medoxomil, ...

A 12-week trial was conducted comparing people who took the combo pill Sevikar HCT to those who took the medicines individually. The pill increased the proportion and lowered the BP to target from ...

The makers of Sevikar HCT hope it will help hundreds of thousands to stick to their medication regimes by making it easier to do so. Some 8.5 million people in Britain have high blood pressure ...

MUNICH, December 20, 2010 /PRNewswire/ -- Daiichi Sankyo Europe announced today that Sevikar HCT(R) is now approved in Germany, the first market to launch this new once-daily three-in-one ...

With the approval of Sevikar HCT(R), Daiichi Sankyo offers physicians a comprehensive range of olmesartan based therapies to help them to successfully treat their patients to the accepted target blood ...